These companies have been focusing on growing their operations, but which stock is likely to provide investors with better returns?
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:AMGN),(NASDAQ:AMAM),(NASDAQ:ELEV),(NASDAQ:NKTX) EQNX::TICKER_END
Johnson & Johnson is actively shifting its strategy towards biotechnology and antibody-drug conjugates, balancing current revenue protection with future growth.
Morning Markets December E-Mini S&P 500 futures (ESZ2 3) are up +0.38%, and the Dec Nasdaq 100 E-Mini futures (NQZ2 3) are up +0.22%. Stock index futures this morning are moderately higher as the markets...
A big buy by an asset manager spurred interest in the biotech stock.
The company reported data on its clinical programs at two conferences this week.
Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), today announced that it has completed net sales of approximately $78 million of American Depositary Shares (“ADSs”) pursuant to the Company’s at-the-market...
After getting a bump on Monday for its switch to the Nasdaq Stock Market, there was a bit of a correction.
Ambrx Pharmaceuticals, Inc. could see positive earnings next year. And while share value could go down, analysts thin rate AMAM a Moderate Buy
Ambrx Biopharma Inc. (NYSE: AMAM ) (“Ambrx” or “the Company”) today announced that it will voluntarily transfer its stock exchange listing to the Nasdaq Stock Market from the New York Stock Exchange,...